December 31, 2021 - January 5, 2022

Fabino Life Sciences IPO Review & Recommendations

Dilip Davda recommend to "Avoid" the IPO.

Fabino Life Sciences IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated
Count	0	0	0	1	0
%	0.00	0.00	0.00	100.00	0.00

Fabino Life Sciences IPO Analysis By Brokers/Analysts

Reviewer	Recommendation	Past Reviews
Dilip Davda	Avoid

Fabino Life Sciences IPO Review by Dilip Davda (Avoid)

[Dilip Davda] The company has posted erratic financial performance with poor earnings in pandemic periods. The issue is exorbitantly priced based on its latest earnings. Higher promoter’s dilution and lower equity base post IPO are concerned. There is no harm in ignoring this pricy issue. Read detail review...

Fabino Life Sciences IPO Review by Members

Fabino Life Sciences IPO Reviews, analysis and views by popular members. Read Fabino Life Sciences Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Fabino Life Sciences IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid

Member	Review
No recommendation found. Be the first to post the recommendation.

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.